J&J beats Q3 earnings estimates, misses sales and raises outlook

J&J beats Q3 earnings estimates, misses sales and raises outlook: the analysis positions JNJ, LEGN and LLY to benefit and PG, UNH and AMGN under pressure; confidence medium.

Analyzed 2026-10-13 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

  1. ▲ JNJ Johnson & Johnson — impact +73 · confidence medium · horizon immediate · 1st order
    Johnson & Johnson’s raised outlook reflects stronger medicine pricing and cost control, expanding earnings despite weaker quarterly sales.
    Chain: Q3 adjusted earnings exceed consensus estimates → innovative medicine pricing and cost control expand margins → full year guidance raised by management → investors reprice forward earnings higher
    What would break the call: A fourth quarter sales miss on Stelara erosion forces guidance back down.
  2. ▲ LEGN Legend Biotech — impact +70 · confidence low · horizon quarters · 2nd order
    Legend Biotech books half of Carvykti profits, so accelerating cell therapy capacity and demand lift its revenue.
    Chain: J&J reports strong Carvykti demand and capacity → Legend shares Carvykti profits equally with J&J → Legend collaboration revenue and profit share rise → consensus myeloma forecasts move higher
    What would break the call: A manufacturing suspension or safety label change halts Carvykti slot expansion.
  3. ▲ LLY Eli Lilly — impact +65 · confidence low · horizon quarters · 3rd order
    Eli Lilly margins improve as J&J earnings beat sets positive precedent for drug pricing power.
    Chain: J&J shows branded pricing holding up → sector read across on pharma pricing power → investors lift margin assumptions for large pharma → Lilly forward estimates drift higher
    What would break the call: Lilly guides down on incretin pricing, breaking the pharma pricing read across.
  4. ▼ PG Procter & Gamble — impact -45 · confidence low · horizon quarters · 3rd order
    Procter and Gamble revenue decreases when J&J raised outlook reflects share gains in consumer health.
    Chain: J&J consumer health was spun into Kenvue → J&J results carry little consumer shelf signal → household staples demand set by trade down behavior → P&G volume link to this print is weak
    What would break the call: P&G reports organic volume growth above consensus, breaking the share loss story.
  5. ▲ ABT Abbott — impact +42 · confidence medium · horizon weeks · 2nd order
    Elevated healthcare activity supports Abbott’s diagnostic volumes and device sales through stronger procedure demand.
    Chain: J&J medtech shows firm procedure volumes → hospital activity read across to diagnostics and devices → Abbott device and testing volumes track utilization → Abbott sales guidance supported
    What would break the call: Abbott guides device sales below consensus on slowing hospital capital budgets.
  6. ▲ SYK Stryker — impact +41 · confidence medium · horizon weeks · 2nd order
    Firm hospital procedure demand strengthens Stryker’s implant sales across orthopedic and surgical markets.
    Chain: J&J orthopedics reports solid implant demand → procedure volume signal applies across orthopedics → Stryker hip and knee unit sales benefit → Stryker revenue growth estimates hold
    What would break the call: Stryker reports decelerating knee and hip procedure growth in its own quarter.
  7. ▼ UNH UnitedHealth — impact -40 · confidence low · horizon weeks · 2nd order
    UnitedHealth pays for the surgical procedures driving J&J device sales, so elevated utilization raises medical costs.
    Chain: device makers confirm high surgical utilization → procedures convert into paid medical claims → UnitedHealth medical loss ratio rises → earnings guidance pressure follows
    What would break the call: UnitedHealth reports a medical loss ratio below guidance, showing utilization contained.
  8. ▲ BSX Boston Scientific — impact +40 · confidence low · horizon weeks · 2nd order
    Boston Scientific competes in electrophysiology where J&J's Varipulse ramp confirms rapid growth in pulsed field ablation.
    Chain: J&J Varipulse ramp confirms pulsed field adoption → category growth validates electrophysiology spending → Boston Scientific Farapulse volumes expand with market → cardiology revenue growth sustained
    What would break the call: Varipulse takes measurable account share from Farapulse in the next quarter.
  9. ▼ AMGN Amgen — impact -37 · confidence medium · horizon quarters · 2nd order
    Johnson & Johnson’s immunology defense limits Amgen’s biosimilar uptake across overlapping biotech markets.
    Chain: J&J defends immunology with Tremfya switching → Stelara biosimilar volume pool shrinks → Amgen Wezlana uptake slows → Amgen biosimilar revenue growth capped
    What would break the call: Payers mandate ustekinumab biosimilar substitution, expanding the convertible volume pool.
  10. ▼ ALVO Alvotech — impact -35 · confidence low · horizon quarters · 2nd order
    Alvotech depends on ustekinumab biosimilar royalties and faster switching to Tremfya shrinks the addressable Stelara pool.
    Chain: Tremfya conversion accelerates away from Stelara → ustekinumab biosimilar addressable market contracts → Alvotech partner sales and royalties fall → Alvotech revenue guidance pressured
    What would break the call: Alvotech lands a new biosimilar approval that offsets ustekinumab royalty decline.
  11. ▼ ELV Elevance Health — impact -35 · confidence low · horizon weeks · 2nd order
    Elevance faces the same utilization signal, with higher orthopedic and cardiac procedure counts pressuring its medical loss ratio.
    Chain: medtech results signal elevated procedure counts → orthopedic and cardiac claims flow to insurers → Elevance medical loss ratio climbs → commercial margin guidance tightens
    What would break the call: Elevance beats on medical loss ratio and reaffirms margin guidance.
  12. ▲ HCA HCA Healthcare — impact +35 · confidence low · horizon weeks · 2nd order
    HCA Healthcare captures the same hospital procedure volumes that drive J&J device and surgery sales.
    Chain: device demand reflects hospital surgical throughput → HCA bills the same inpatient procedures → admissions and surgical revenue per case rise → HCA revenue growth supported
    What would break the call: HCA reports flat same facility surgical volumes in its quarterly update.
  13. ▲ TMO Thermo Fisher — impact +35 · confidence low · horizon quarters · 2nd order
    Thermo Fisher supplies pharma manufacturing inputs and raised drugmaker spending guidance supports its bioproduction order volumes.
    Chain: pharma raises outlook and sustains R and D spend → bioproduction and lab input orders stay firm → Thermo Fisher bioprocessing revenue improves → order book visibility increases
    What would break the call: Thermo Fisher guides bioprocessing orders lower on continued customer destocking.
  14. ▼ TEVA Teva — impact -34 · confidence medium · horizon immediate · 3rd order
    Johnson & Johnson’s branded pharmaceutical strength slows Teva’s biosimilar conversions across generic markets.
    Chain: J&J brand defense slows biosimilar switching → Teva partnered biosimilar volumes undershoot → Teva generics segment growth stays modest → revenue mix shifts toward innovative assets
    What would break the call: Teva reports biosimilar revenue above plan on faster payer substitution.
  15. ▲ WST West Pharmaceutical Services — impact +33 · confidence low · horizon quarters · 2nd order
    West Pharmaceutical ships injectable containment components so higher biologic volumes at large drugmakers raise unit shipments.
    Chain: biologic drug volumes grow at large pharma → injectable fill finish components demand rises → West unit shipments and mix improve → proprietary products revenue grows
    What would break the call: West flags renewed customer destocking in high value components next quarter.
  16. ▼ HUM Humana — impact -32 · confidence low · horizon quarters · 2nd order
    Humana's Medicare Advantage members account for many implant procedures and rising volumes lift claims expense.
    Chain: implant and cardiac procedures run above plan → Medicare Advantage members drive much of that volume → Humana benefit expense ratio rises → earnings per share guidance pressured
    What would break the call: Humana reports a benefit ratio in line and reaffirms its earnings target.
  17. ▼ AZN AstraZeneca — impact -30 · confidence low · horizon quarters · 2nd order
    AstraZeneca's Tagrisso franchise loses lung cancer share as J&J's Rybrevant and Lazcluze combination expands prescriptions.
    Chain: J&J grows Rybrevant and Lazcluze prescriptions → EGFR lung cancer share shifts from osimertinib → AstraZeneca Tagrisso volume growth slows → oncology revenue growth decelerates
    What would break the call: AstraZeneca reports accelerating Tagrisso sales, showing no share erosion.
  18. ▼ KMB Kimberly-Clark — impact -30 · confidence low · horizon weeks · 3rd order
    Kimberly Clark sales volumes fall after J&J earnings report signals competitive pressure in personal care.
    Chain: J&J no longer sells consumer personal care → results carry no direct shelf competition signal → staples capital rotates toward healthcare earnings → Kimberly Clark multiple drifts lower
    What would break the call: Kimberly Clark posts organic sales growth ahead of consensus on volume recovery.
  19. ▲ ISRG Intuitive Surgical — impact +30 · confidence low · horizon quarters · 3rd order
    Intuitive Surgical system sales increase after J&J raised outlook predicts growth in surgical procedures.
    Chain: surgical procedure volumes confirmed healthy → hospitals sustain capital and robotics budgets → Intuitive procedure growth and placements hold → recurring instrument revenue rises
    What would break the call: Intuitive guides procedure growth lower as hospitals defer capital purchases.
  20. ▼ BMY Bristol Myers — impact -25 · confidence high · horizon quarters · 2nd order
    Johnson & Johnson’s expanding oncology investment takes treatment share from Bristol Myers Squibb’s competing myeloma therapies.
    Chain: Carvykti capacity expands in multiple myeloma → treatment share shifts toward cell therapy → Bristol Abecma and Pomalyst volumes decline → Bristol oncology revenue growth weakens
    What would break the call: Bristol reports stabilizing Abecma and myeloma franchise revenue next quarter.
  21. ▼ CL Colgate-Palmolive — impact -25 · confidence low · horizon quarters
    Colgate revenue declines when J&J sales miss indicates weak consumer demand trends.
  22. ▲ IQV IQVIA — impact +25 · confidence low · horizon quarters
    IQVIA earns fees from clinical trials and stronger pharma guidance sustains research outsourcing bookings.
  23. ▼ CNC Centene — impact -22 · confidence low · horizon quarters
    Centene carries managed care exposure to procedure inflation, which compresses margins when device utilization accelerates.
  24. ▼ CVS CVS Health — impact -22 · confidence low · horizon quarters · 2nd order
    Aetna membership absorbs the same elevated surgical utilization, lifting medical benefit expense and pressuring insurance segment margin.
    Chain: device sales confirm high procedure counts → Aetna members generate those surgical claims → CVS medical benefit ratio rises → insurance segment operating income falls
    What would break the call: CVS reports a medical benefit ratio below guidance and raises insurance margin outlook.

Sources

More

Related scenarios

Stocks in this scenario

JNJ · LEGN · LLY · PG · ABT · SYK · UNH · BSX · AMGN · ALVO · ELV · HCA · TMO · TEVA · WST · HUM · AZN · KMB · ISRG · BMY · CL · IQV · CNC · CVS · MCK · DHR · ABBV · BDX · GEHC · MDT · MRK · PFE · EW

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario